Loading
This study tests a PARP inhibitor; the registry reports that it is terminated.
The registry lists NCT04182516 as terminated, last updated 2024-09-19. Enrolment is 52 actual participants. Interventions: NMS-03305293. Primary measures include Number of Participants with first-cycle dose limiting toxicity. The registry reason for stopping is: The study closure is related to sponsor decision to shift towards the clinical development of NMS-03305293 in combination in a broader range of indication and not based on emerging safety or efficacy concerns. No results are posted in the registry; this does not exclude separate publications.
Shares NMS-03305293, PARP.
Shares NMS-03305293, PARP.
Shares NMS-03305293, PARP.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/